Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries
Authors:
- Corrado BarbuiCBCorrado Barbui
- Michela NosMNMichela Nos
- Maria Angela MazziMMMaria Angela Mazzi
- Graham ThornicroftGTGraham Thornicroft
- Aart ScheneASAart Schene
- Thomas BeckerTBThomas Becker
- Jonathan BindmanJBJonathan Bindman
- Morven LeeseMLMorven Leese
- Hedda HelmHHHedda Helm
- Maarten KoeterMKMaarten Koeter
- Stefan WeinmannSWStefan Weinmann
- Michele TansellaMTMichele Tansella
- 1 November 2006
- journal article
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 21 (6) , 355-362
Abstract
The purpose of this study was to calculate the proportion of patients with schizophrenia receiving persistent antipsychotic polypharmacy and excessive dosing in four European countries; to test the hypothesis that excessive dosing and/or antipsychotic polypharmacy is associated with higher levels of psychopathology; and to establish whether use of second-generation antipsychotics is a protective or a risk factor for polypharmacy and excessive dosing. Participants with schizophrenia were recruited from patients under the care of psychiatric services serving geographical catchment areas in Croydon (UK), Verona (Italy), Amsterdam (Netherlands), and Leipzig (Germany). We defined patients persistently receiving high antipsychotic dose (i.e. excessive dosing) as those with a prescribed daily dose/defined daily dose ratio of >1.5 both at initial assessment and after 1 year of follow-up. Similarly, we defined patients persistently receiving polypharmacy as those being prescribed two or more antipsychotic drugs both at baseline and at follow-up. A sample of 375 participants with schizophrenia was analyzed. A proportion of 28% of patients persistently received high-dose antipsychotic drugs, and a proportion of 13% of patients persistently received antipsychotic polypharmacy. In the multivariate analysis, psychopathology was not a predictor of persistent polypharmacy and excessive dosing; similarly, use of second-generation antipsychotics was not associated with polypharmacy and excessive dosing; however, persistence with high antipsychotic doses was predicted by baseline use of first-generation antipsychotics and second-generation antipsychotics concurrently. Antipsychotic drug use for patients with schizophrenia is only sometimes satisfactory and offers the opportunity of improvement. Clinicians should consider that dose reduction strategies have been shown to be a feasible intervention in patients with schizophrenia.Keywords
This publication has 23 references indexed in Scilit:
- Sex Differences in the Subjective Tolerability of Antipsychotic DrugsJournal of Clinical Psychopharmacology, 2005
- Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective studyInternational Clinical Psychopharmacology, 2005
- Use of combinations of antipsychotics: McLean Hospital inpatients, 2002Human Psychopharmacology: Clinical and Experimental, 2005
- Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophreniaEvidence Based Mental Health, 2005
- Drug treatment modalities in psychiatric inpatient practiceEuropean Archives of Psychiatry and Clinical Neuroscience, 2004
- Prevalence, Trends, and Factors Associated With Antipsychotic Polypharmacy Among Medicaid-Eligible Schizophrenia Patients, 1998–2000The Journal of Clinical Psychiatry, 2004
- Inpatient Antipsychotic Drug Use in 1998, 1993, and 1989American Journal of Psychiatry, 2002
- Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinationsActa Psychiatrica Scandinavica, 2002
- Provision of services for people with schizophrenia in five European regionsSocial Psychiatry and Psychiatric Epidemiology, 2002
- Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E)Psychopharmacology, 1995